DK2961420T3 - Fremgangsmåder og sammensætninger til forebyggelsen eller behandlingen af barth syndrom - Google Patents

Fremgangsmåder og sammensætninger til forebyggelsen eller behandlingen af barth syndrom Download PDF

Info

Publication number
DK2961420T3
DK2961420T3 DK14756991.7T DK14756991T DK2961420T3 DK 2961420 T3 DK2961420 T3 DK 2961420T3 DK 14756991 T DK14756991 T DK 14756991T DK 2961420 T3 DK2961420 T3 DK 2961420T3
Authority
DK
Denmark
Prior art keywords
prevention
compositions
treatment
methods
barth syndrome
Prior art date
Application number
DK14756991.7T
Other languages
English (en)
Inventor
D Travis Wilson
Mark Bamberger
Original Assignee
Stealth Biotherapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stealth Biotherapeutics Corp filed Critical Stealth Biotherapeutics Corp
Application granted granted Critical
Publication of DK2961420T3 publication Critical patent/DK2961420T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DK14756991.7T 2013-03-01 2014-02-28 Fremgangsmåder og sammensætninger til forebyggelsen eller behandlingen af barth syndrom DK2961420T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361771534P 2013-03-01 2013-03-01
US201361771642P 2013-03-01 2013-03-01
US201361839753P 2013-06-26 2013-06-26
PCT/US2014/019622 WO2014134554A1 (en) 2013-03-01 2014-02-28 Methods and compositions for the prevention or treatment of barth syndrome

Publications (1)

Publication Number Publication Date
DK2961420T3 true DK2961420T3 (da) 2019-10-07

Family

ID=51428869

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14756991.7T DK2961420T3 (da) 2013-03-01 2014-02-28 Fremgangsmåder og sammensætninger til forebyggelsen eller behandlingen af barth syndrom

Country Status (9)

Country Link
US (5) US9687519B2 (da)
EP (2) EP2961420B1 (da)
JP (4) JP6518197B2 (da)
CN (3) CN115990241A (da)
CA (1) CA2916880C (da)
DK (1) DK2961420T3 (da)
ES (1) ES2750258T3 (da)
HU (1) HUE046924T2 (da)
WO (1) WO2014134554A1 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105517533A (zh) 2013-03-01 2016-04-20 康德生物医疗技术公司 治疗线粒体疾病的方法
DK2961420T3 (da) * 2013-03-01 2019-10-07 Stealth Biotherapeutics Corp Fremgangsmåder og sammensætninger til forebyggelsen eller behandlingen af barth syndrom
CA2916977A1 (en) 2013-06-26 2014-12-31 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions
US9550981B2 (en) 2014-01-22 2017-01-24 University Of Washington Modified tafazzin proteins and methods of making and using the same
EP3230308B1 (en) * 2014-12-12 2019-05-01 University of Washington Methods for treating and preventing cardiomyopathy
WO2018104172A1 (en) 2016-12-06 2018-06-14 Centre National De La Recherche Scientifique (Cnrs) Compounds for treating barth syndrome
WO2018187400A1 (en) 2017-04-05 2018-10-11 Stealth Biotherapeutics Corp. Crystalline salt forms of boc-d-arg-dmt-lys-(boc)-phe-nh2
US10676506B2 (en) 2018-01-26 2020-06-09 Stealth Biotherapeutics Corp. Crystalline bis- and tris-hydrochloride salt of elamipretide

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
US7435578B2 (en) 2001-08-06 2008-10-14 Vanderbilt University Device and methods for monitoring the status of at least one cell
BRPI0105509B8 (pt) 2001-11-05 2021-05-25 Univ Minas Gerais formulações do peptídeo angiotensina-(1-7) usando as ciclodextrinas, lipossomas e o polímero plga
EP3144009A1 (en) 2003-02-04 2017-03-22 Cornell Research Foundation, Inc. Uses of aromatic-cationic peptide
CN101440124B (zh) 2003-02-04 2012-07-18 科内尔研究基金会 用于防止线粒体通透性改变的方法
WO2004069866A1 (en) * 2003-02-10 2004-08-19 Autogen Research Pty Ltd Therapeutic molecules
WO2005023274A1 (en) 2003-09-05 2005-03-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Treatment and prevention of inflammatory disease and mitochondrial dysfunction with high dose selenium
CA2554166C (en) 2004-01-23 2014-07-29 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
US8500720B2 (en) 2005-05-09 2013-08-06 Medtronic, Inc Method and apparatus for treatment of cardiac disorders
US20070265216A1 (en) * 2005-10-05 2007-11-15 Gross Richard W Enhanced medical treatment in diabetic cardiomyopathy
US20090298848A1 (en) * 2006-04-18 2009-12-03 Cortendo Invest Ab, Methods and Compositions for Treating Barth Syndrome, Cardiomyopathy, Mitochondrial Diseases and Other Conditions
EP2641617A1 (en) 2007-05-02 2013-09-25 THE McLEAN HOSPITAL CORPORATION Methods and compositions for mitochondrial replacement therapy
US20080318909A1 (en) 2007-06-14 2008-12-25 Sparagna Genevieve C Use Of Linoleic Compounds Against Heart Failure
US20090143279A1 (en) 2007-06-15 2009-06-04 Vamsi Krishna Mootha Methods and compositions for treating metabolic disorders
CN101951936A (zh) 2008-02-26 2011-01-19 康奈尔大学 用于防止和治疗急性肾损伤的方法
WO2009149307A2 (en) 2008-06-04 2009-12-10 San Diego State University Research Foundation Compositions and methods for restoring mitochondrial electron transfer function
KR101593158B1 (ko) 2008-08-07 2016-02-12 입센 파마 에스.에이.에스. Ｎ-말단이 변형된 포도당 의존적인 인슐린 분비 자극성 폴리펩타이드(ｇｉｐ)의 유사체
CN102573881A (zh) 2009-03-20 2012-07-11 通用医疗公司以马萨诸塞州通用医疗公司名义经营 预防和治疗烧伤损伤和继发性并发症的方法
US20120122957A1 (en) 2009-04-17 2012-05-17 The Salk Institute For Biological Studies Regulation of aging by modulation of mitochondrial function
WO2010132347A2 (en) 2009-05-11 2010-11-18 University Of Maryland, Baltimore Docosahexaenoic acid for the treatment of heart failure
CN102647994A (zh) 2009-08-12 2012-08-22 康奈尔大学 预防或治疗代谢综合症的方法
EP2470191B1 (en) * 2009-08-24 2014-05-07 Stealth Peptides International, Inc. Methods and compositions for preventing or treating ophthalmic conditions
CN102711785A (zh) * 2009-10-05 2012-10-03 康奈尔大学 预防或治疗心力衰竭的方法
WO2011082355A1 (en) 2009-12-31 2011-07-07 Edison Pharmaceuticals, Inc. Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones
WO2011082324A1 (en) 2009-12-31 2011-07-07 Stealth Peptides International, Inc. Methods for the prevention or treatment of vessel occlusion injury
US8719939B2 (en) 2009-12-31 2014-05-06 Mcafee, Inc. Malware detection via reputation system
JP4643749B1 (ja) 2010-02-03 2011-03-02 昭和電工株式会社 表面被覆サーメット部材の耐酸化膜形成用の処理液
JP2013521231A (ja) * 2010-02-26 2013-06-10 ユニバーシティ オブ フロリダ リサーチ ファウンデーション インコーポレイテッド ミトコンドリア標的化抗酸化剤は機械的人工呼吸誘発性横隔膜機能障害および骨格筋萎縮を防止する
EP2808029A3 (en) * 2010-03-15 2015-04-01 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides
JP2013532124A (ja) 2010-05-03 2013-08-15 ステルス ペプチドズ インターナショナル インコーポレイテッド 芳香族系陽イオンペプチド及びその使用
US20130288985A1 (en) 2010-07-15 2013-10-31 The Schepens Eye Research Institute Inc. Compositions and methods of treatment of corneal endothelium disorders
EP2601168A4 (en) 2010-08-06 2013-12-04 Ampere Life Sciences Inc TREATMENT OF MITOCHONDRIAL DISEASES BY VITAMIN K
US20130345312A1 (en) 2010-08-06 2013-12-26 Orion D. Jankowski Treatment of mitochondrial diseases with naphthoquinones
US9241933B2 (en) 2011-03-01 2016-01-26 Pharnext Compositions for treating amyotrophic lateral sclerosis
EP2688579A4 (en) 2011-03-24 2015-10-21 Univ Cornell AROMATIC-CATIONIC PEPTIDES AND USES THEREOF
JP6157481B2 (ja) 2011-09-29 2017-07-05 メイヨ ファンデーション フォア メディカル エディケイション アンド リサーチ 芳香族陽イオン性ペプチドおよびその使用方法
WO2013059071A1 (en) 2011-10-17 2013-04-25 Cornell University Aromatic-cationic peptides and uses of same
KR20200040924A (ko) * 2011-10-21 2020-04-20 스템제닉스 인코포레이티드 생물학적 활성 분자의 세포내 전달을 위한 작용화 나노입자
EP3479839A1 (en) 2012-02-22 2019-05-08 Stealth Peptides International, Inc. Methods and compositions for preventing or treating opthalmic conditions
EP2817021B1 (en) * 2012-02-23 2019-01-02 Cornell University Aromatic-cationic peptides and uses of same
AU2013329312A1 (en) 2012-10-09 2015-05-28 Massachusetts Institute Of Technology Treatment of age-related and mitochondrial diseases by inhibition of HIF-1 alpha function
JP2016503397A (ja) * 2012-10-22 2016-02-04 ステルス ペプチドズ インターナショナル インコーポレイテッド 心不全関連リスクおよびそれらと関連する因子を減少させる方法
CN105517533A (zh) 2013-03-01 2016-04-20 康德生物医疗技术公司 治疗线粒体疾病的方法
DK2961420T3 (da) 2013-03-01 2019-10-07 Stealth Biotherapeutics Corp Fremgangsmåder og sammensætninger til forebyggelsen eller behandlingen af barth syndrom
CA2916977A1 (en) * 2013-06-26 2014-12-31 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions

Also Published As

Publication number Publication date
EP2961420A1 (en) 2016-01-06
US20180147251A1 (en) 2018-05-31
CN115990241A (zh) 2023-04-21
JP2019147815A (ja) 2019-09-05
US11083771B2 (en) 2021-08-10
WO2014134554A1 (en) 2014-09-04
US20160228487A1 (en) 2016-08-11
JP6518197B2 (ja) 2019-05-22
JP2021098704A (ja) 2021-07-01
EP3626252A1 (en) 2020-03-25
CA2916880A1 (en) 2014-09-04
US20200345803A1 (en) 2020-11-05
JP2016511259A (ja) 2016-04-14
US20210401923A1 (en) 2021-12-30
EP2961420B1 (en) 2019-09-11
US20240156892A1 (en) 2024-05-16
CN105407906A (zh) 2016-03-16
US9687519B2 (en) 2017-06-27
HUE046924T2 (hu) 2020-03-30
JP6918046B2 (ja) 2021-08-11
JP7072692B2 (ja) 2022-05-20
US11083772B2 (en) 2021-08-10
CN115990242A (zh) 2023-04-21
JP2022116008A (ja) 2022-08-09
ES2750258T3 (es) 2020-03-25
JP7381652B2 (ja) 2023-11-15
EP2961420A4 (en) 2016-08-17
US11771734B2 (en) 2023-10-03
CA2916880C (en) 2021-02-09

Similar Documents

Publication Publication Date Title
DK3364993T3 (da) Fremgangsmåder til behandling af angelman syndrom
DK3234133T3 (da) Crispr-baserede sammensætninger og fremgangsmåder til anvendelse
DK3102673T3 (da) Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3119797T3 (da) Raav-baserede sammensætninger og fremgangsmåder til behandling af amyotrofisk lateralsklerose
DK2906698T3 (da) Fremgangsmåde til behandling af alports syndrom
DK2898061T3 (da) Probiotiske sammensætninger til behandlingen af fedme og fedme-relaterede tilstande
DK2961831T3 (da) Sammensætninger og fremgangsmåder til immunterapi
DK3227675T3 (da) Activin-actrii-antagonister og anvendelser til behandling af myelodysplastisk syndrom
DK3008168T3 (da) Sc-celler og sammensætninger og fremgangsmåde til dannelse deraf
DK3693158T3 (da) Asymmetrisk forarbejdningsfremgangsmåde til krumningsreduktion i laminatstrukturer
DK3252160T3 (da) Systemer, fremgangsmåder og sammensætninger med crispr-cas-bestanddele til sekvensmanipulation
DK2841097T3 (da) Sammensætninger og fremgangsmåder til behandling og forebyggelse af porcint reproduktions- og respirationssyndrom
DK2961420T3 (da) Fremgangsmåder og sammensætninger til forebyggelsen eller behandlingen af barth syndrom
DK3144001T3 (da) Sammensætninger af selenoorganiske forbindelser og fremgangsmåder til anvendelse deraf
DK3007695T3 (da) Sammensætninger og fremgangsmåder til behandling af anæmi
DK2854850T3 (da) Sammensætninger til behandling eller forebyggelse af strålingssygdom og gi-syndrom
DK3393655T3 (da) Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme
DK3238707T3 (da) Sammensætninger og fremgangsmåder til behandling af intestinal hyperpermeabilitet
DK3209696T3 (da) Fremgangsmåder og sammensætninger til diagnosticering og behandling af glioblastom
DK3189074T3 (da) Sammensætninger og metoder til behandling og forebyggelse af inflammation
DK3366307T3 (da) Sammensætninger og fremgangsmåder til inhibering af masp-1 og/eller masp-3 til behandling af paroxystisk nokturn hæmoglobinuri
DK3033081T3 (da) Sammensætninger og fremgangsmåder til behandling af kronisk urticaria
DK3217963T3 (da) Fremgangsmåder til behandling af individer med prader-willis syndrom eller smith-magenis syndrom
DK3212776T3 (da) Sammensætninger og fremgangsmåder i forbindelse med beta-glucosidase
DK3394259T3 (da) Sammensætninger og fremgangsmåder til reducering af tau-ekspression